160 related articles for article (PubMed ID: 33023437)
1. Anti-cancer Immunotoxins, Challenges, and Approaches.
Dashtiahangar M; Rahbarnia L; Farajnia S; Salmaninejad A; Shabgah AG; Ghasemali S
Curr Pharm Des; 2021; 27(7):932-941. PubMed ID: 33023437
[TBL] [Abstract][Full Text] [Related]
2. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
3. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
Mathew M; Verma RS
Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
[TBL] [Abstract][Full Text] [Related]
4. Immunotoxins in cancer therapy: Review and update.
Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
[TBL] [Abstract][Full Text] [Related]
5. Advances in anticancer immunotoxin therapy.
Alewine C; Hassan R; Pastan I
Oncologist; 2015 Feb; 20(2):176-85. PubMed ID: 25561510
[TBL] [Abstract][Full Text] [Related]
6. Patents on immunotoxins and chimeric toxins for the treatment of cancer.
Bachran C; Sutherland M; Bachran D; Fuchs H
Recent Pat Drug Deliv Formul; 2007; 1(2):105-15. PubMed ID: 19075878
[TBL] [Abstract][Full Text] [Related]
7. Clinical targeting recombinant immunotoxins for cancer therapy.
Li M; Liu ZS; Liu XL; Hui Q; Lu SY; Qu LL; Li YS; Zhou Y; Ren HL; Hu P
Onco Targets Ther; 2017; 10():3645-3665. PubMed ID: 28790855
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxins: the role of the toxin.
Antignani A; Fitzgerald D
Toxins (Basel); 2013 Aug; 5(8):1486-502. PubMed ID: 23965432
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxins in cancer therapy.
Kreitman RJ
Curr Opin Immunol; 1999 Oct; 11(5):570-8. PubMed ID: 10508704
[TBL] [Abstract][Full Text] [Related]
10. Immunotoxins for targeted cancer therapy.
Kreitman RJ
AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
[TBL] [Abstract][Full Text] [Related]
11. Immunotoxin therapy of cancer.
Pastan I; Hassan R; Fitzgerald DJ; Kreitman RJ
Nat Rev Cancer; 2006 Jul; 6(7):559-65. PubMed ID: 16794638
[TBL] [Abstract][Full Text] [Related]
12. Bacterial Toxins for Cancer Therapy.
Zahaf NI; Schmidt G
Toxins (Basel); 2017 Jul; 9(8):. PubMed ID: 28788054
[TBL] [Abstract][Full Text] [Related]
13. Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins.
Mazor R; King EM; Pastan I
Am J Pathol; 2018 Aug; 188(8):1736-1743. PubMed ID: 29870741
[TBL] [Abstract][Full Text] [Related]
14. Chimeric fusion proteins--Pseudomonas exotoxin-based.
Kreitman RJ
Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.
Shan L; Liu Y; Wang P
J Basic Clin Med; 2013; 2(2):1-6. PubMed ID: 25309827
[TBL] [Abstract][Full Text] [Related]
16. Recombinant immunotoxins for cancer therapy.
Brinkmann U; Keppler-Hafkemeyer A; Hafkemeyer P
Expert Opin Biol Ther; 2001 Jul; 1(4):693-702. PubMed ID: 11727505
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.
Zhu S; Liu Y; Wang PC; Gu X; Shan L
Biomed Res Int; 2017; 2017():7929286. PubMed ID: 28752098
[TBL] [Abstract][Full Text] [Related]
18. Designing immunotoxins for cancer therapy.
Pennell CA; Erickson HA
Immunol Res; 2002; 25(2):177-91. PubMed ID: 11999171
[TBL] [Abstract][Full Text] [Related]
19. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxin treatment of cancer.
Pastan I; Hassan R; FitzGerald DJ; Kreitman RJ
Annu Rev Med; 2007; 58():221-37. PubMed ID: 17059365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
